Conversely, engineering CD19 CAR T cells with hypoxia-controlled IL-12 may offer a safer, more targeted modality for treating diffuse large B-cell lymphoma (DLBCL) 15. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.